Page last updated: 2024-08-16

sibutramine and mk-0557

sibutramine has been researched along with mk-0557 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S	1

Trials

1 trial(s) available for sibutramine and mk-0557

Article	Year
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring, Md.), 2007, Volume: 15, Issue:8 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Pyrazoles; Receptors, Neuropeptide Y; Spiro Compounds; Weight Loss	2007

Article

Year

NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

Obesity (Silver Spring, Md.), 2007, Volume: 15, Issue:8

Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Pyrazoles; Receptors, Neuropeptide Y; Spiro Compounds; Weight Loss

2007